The DOI matches its Crossref record.
Modification of Alternative Splicing of Bcl-x Pre-mRNA in Prostate and Breast Cancer Cells
Open accessAbstract
There is ample evidence that deregulation of apoptosis results in the development, progression, and/or maintenance of cancer. Since many apoptotic regulatory genes (e.g. bcl-x) code for alternatively spliced protein variants with opposing functions, the manipulation of alternative splicing presents a unique way of regulating the apoptotic response. Here we have targeted oligonucleotides antisense to the 5'-splice site of bcl-x(L), an anti-apoptotic gene that is overexpressed in various cancers, and shifted the splicing pattern of Bcl-x pre-mRNA from Bcl-x(L) to Bcl-x(S), a pro-apoptotic splice variant. This approach induced significant apoptosis in PC-3 prostate cancer cells. In contrast, the same oligonucleotide treatment elicited a much weaker apoptotic response in MCF-7 breast cancer cells. Moreover, although the shift in Bcl-x pre-mRNA splicing inhibited colony formation in both cell lines, this effect was much less pronounced in MCF-7 cells. These differences in responses to oligonucleotide treatment were analyzed in the context of expression of Bcl-x(L), Bcl-x(S), and Bcl-2 proteins. The results indicate that despite the presence of Bcl-x pre-mRNA in a number of cell types, the effects of modification of its splicing by antisense oligonucleotides vary depending on the expression profile of the treated cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
RNA therapeutics: beyond RNA interference and antisense oligonucleotides
Kole, R., Krainer, A. R., & Altman, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3625 · Cited by 1,152
Self-citationRoles and mechanisms of alternative splicing in cancer — implications for care
Bonnal, S. C., López-Oreja, I., & Valcárcel, J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0350-x · Cited by 731
RNA splicing dysregulation and the hallmarks of cancer
Bradley, R. K., & Anczuków, O. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00541-7 · Cited by 579
Nucleic-acid therapeutics: basic principles and recent applications
Opalinska, J. B., & Gewirtz, A. M. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd837 · Cited by 537
Urbanski, L. M., Leclair, N., & Anczuków, O. (2018) · WIREs RNA · doi:10.1002/wrna.1476 · Cited by 389
Chalfant, C. E., Rathman, K., Pinkerman, R. L., Wood, R. E., Obeid, L. M., Ogretmen, B., & Hannun, Y. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m112010200 · Cited by 337
Mcl-1 is a potential therapeutic target in multiple types of cancer
Akgul, C. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8637-6 · Cited by 329
Systemically delivered antisense oligomers upregulate gene expression in mouse tissues
Sazani, P., Gemignani, F., Kang, S.-H., Maier, M. A., Manoharan, M., Persmark, M., Bortner, D., & Kole, R. (2002) · Nature Biotechnology · doi:10.1038/nbt759 · Cited by 301
Self-citationCraig, R. (2002) · Leukemia · doi:10.1038/sj.leu.2402416 · Cited by 266
Splicing factors of SR and hnRNP families as regulators of apoptosis in cancer
Kędzierska, H., & Piekiełko-Witkowska, A. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.03.013 · Cited by 262
Metadata
- Authors
- Mercatante, D. R., Bortner, C. D., Cidlowski, J. A., & Kole, R.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2001-05
- Volume
- 276
- Issue
- 19
- Pages
- 16411-16417
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2079050210
- Cited by
- 163
- References
- 0
- FWCI
- 4.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.